Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CTH | P32929 | 1/20 | 0.30 |
| ▸ | CBS | P35520 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574208 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2ATDP1SLC6A4TSHR | |
| SCHEMBL25062278 | 0.86 | MEN1 (0.33) | MEN1KMT2ATDP1SLC6A4TSHR | |
| SCHEMBL25255150 | 0.83 | MEN1 (0.34) | MEN1KMT2ATDP1SLC6A2SLC6A4 | |
| SCHEMBL29316573 | 0.82 | CES2 (0.33) | MEN1KMT2ATDP1TSHR | |
| SCHEMBL6993496 | 0.82 | MEN1 (0.30) | MEN1KMT2ATDP1 | |
| SCHEMBL23703846 | 0.81 | MEN1 (0.34) | MEN1KMT2ATDP1BLMPMP22 | |
| SCHEMBL21634360 | 0.79 | MEN1 (0.39) | MEN1KMT2ATDP1 | |
| SCHEMBL1254697 | 0.79 | ALDH1A1 (0.38) | MEN1KMT2ATDP1SLC6A2SLC6A4 | |
| SCHEMBL13193210 | 0.78 | CES2 (0.46) | MEN1KMT2ATDP1TSHR | |
| SCHEMBL29053225 | 0.78 | CHRNB2 (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345932-B1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-10-18 | — | — | EP | disclosed |
| EP-1345932-A1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-6498156-B2 | TREATING HYPERLIPIDEMIA, ARTERIOSCLEROSIS AND HYPERCHOLESTEROLEMIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002050068-A1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | MEN1 1043/4885KMT2A 3423/4885TDP1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.